Personalized CRISPR Remission™ for Sarcoidosis: A Model for State-Dependent Precision Medicine
- 4 days ago
- 29 min read
Updated: 3 days ago
A systems-level framework for aligning gene editing with immune state, environmental load, and diagnostic variability to achieve safer, more durable remission in sarcoidosis and related immune-mediated conditions.
This paper is part of the CYNAERA CRISPR Remission™ Library, an industry defining resource shifting how gene editing is applied to immune-volatile conditions through personalized CRISPR gene editing application. This paper introduces a new state-dependent CRISPR framework specifically applied to sarcoidosis and granulomatous disease.
By Cynthia Adinig
Executive Summary
Sarcoidosis is an immune-mediated disease characterized by granuloma formation and highly variable clinical outcomes, ranging from spontaneous remission to progressive multi-organ involvement. Traditional models attribute this variability to incomplete biological understanding, but emerging evidence suggests it reflects differences in immune state, environmental exposure, and system-level conditions. This paper introduces a state-dependent framework for sarcoidosis, in which disease behavior and treatment response are determined by the configuration of the system at a given point in time. Within this model, variability is not random but structured, arising from the interaction between genetic susceptibility, immune signaling, and environmental inputs.
Building on this foundation, we propose Personalized CRISPR Remission™, a CYNAERA framework that applies gene editing within a state-dependent context. Rather than treating CRISPR as a static intervention, this approach aligns editing with immune stability, environmental load, and phenotype-specific biology to improve safety and increase the likelihood of durable remission.
Using CYNAERA’s Diagnostic Multiplier™ (DM™), we further demonstrate that sarcoidosis burden is underestimated in traditional models. CYNAERA estimates an adjusted sarcoidosis population of approximately 240,000–250,000 individuals, amplifying both clinical and economic impact. State-dependent optimization improves response predictability, reduces treatment inefficiency, and creates measurable system-level cost savings, positioning sarcoidosis as a model for next-generation precision medicine.
1. Sarcoidosis as a Dynamic, Context-Dependent Disease
Sarcoidosis is an immune-mediated disease characterized by non-caseating granulomas and highly variable clinical outcomes, making it a compelling model for personalized CRISPR Remission™ within a state-dependent precision medicine framework. While traditionally described as a condition of unknown origin, this definition does not adequately account for the wide range of disease trajectories observed in practice. Some patients experience spontaneous remission, while others develop persistent inflammation, multi-organ involvement, or progressive fibrosis requiring long-term intervention (Bokhari et al., 2023). This variability has often been attributed to incomplete biological understanding, but emerging evidence suggests it reflects differences in immune state, environmental exposure, and system-level conditions rather than randomness alone.
A growing body of research demonstrates that sarcoidosis is shaped by the interaction between genetic susceptibility, immune signaling pathways, and environmental inputs, including antigen exposure, air quality, and microbial burden (Liao et al., 2023; Rivera & Israël-Biet, 2025). These factors do not operate independently. They continuously influence disease behavior, treatment response, and the likelihood of achieving durable remission. Within this context, sarcoidosis is better understood not as a fixed diagnosis, but as a state-dependent condition in which outcomes are determined by the configuration of the system at a given point in time.
This framing is reinforced by genetic data showing that sarcoidosis does not behave like a single uniform disease. Genome-wide association studies have identified multiple susceptibility loci, including IL23R and HLA-associated regions, which are linked to T-cell activation, cytokine signaling, and leukocyte adhesion pathways (Yuan et al., 2025). However, these genetic signals do not reliably predict disease severity, organ involvement, or trajectory. Instead, they function more as enabling architecture within the disease system, defining possible pathways without determining outcome. This disconnect between genetic risk and clinical expression points toward additional layers of influence that operate continuously in real time.
Those layers increasingly include environmental inputs and immune-state variability, both of which shape how sarcoidosis manifests and evolves over time. The disease does not emerge in isolation, nor does it remain static after diagnosis. A clinical label captures only a moment within a continuously shifting system. At any given point, disease state reflects the cumulative interaction between antigen exposure, immune activation, regulatory balance, and external conditions such as air quality, microbial burden, occupational exposure, and housing environment. This terrain-based perspective aligns with CYNAERA’s broader modeling approach, in which chronic conditions are understood as dynamic systems rather than fixed diagnoses, as outlined in The Science of IACC Remission (Adinig, 2026).
Despite advances in clinical characterization and imaging, sarcoidosis burden is often treated as fully captured within existing surveillance systems. CYNAERA addresses this through a different modeling lens. Disease prevalence is not solely a function of biology, but of how consistently a condition is recognized, evaluated, and formally diagnosed across healthcare systems. To address this, CYNAERA applies the Diagnostic Multiplier™ (DM™), a standardized framework that adjusts observed prevalence based on six drivers of diagnostic undercapture: stigma burden, physician education gaps, diagnostic limitations, referral dependence, underrecognized subgroup burden, and late detection bias. This approach has been applied across both chronic illness and oncology contexts where real-world disease burden exceeds formally recorded estimates.
For sarcoidosis, a moderate adjustment is appropriate. While the condition is clinically recognized, diagnostic capture remains uneven due to non-specific symptom presentation, reliance on imaging and biopsy, variability in provider familiarity, and the need for specialist referral across pulmonary, rheumatologic, and multi-organ domains (Iannuzzi et al., 2007; Drent et al., 2021). Additional factors include underrecognition of atypical phenotypes, including cardiac and neurologic sarcoidosis, as well as disparities in diagnostic patterns across race, gender, and access to care (Arkema et al., 2016). Using an observed U.S. prevalence estimate of approximately 200,000 individuals and a Diagnostic Multiplier of 1.22, CYNAERA estimates an adjusted sarcoidosis population of approximately 240,000–250,000 individuals. This adjustment reflects meaningful but not extreme diagnostic friction, consistent with a condition that is recognized but variably captured depending on presentation and system context.
Within a state-dependent framework, this adjustment is not merely descriptive. Underestimation of prevalence also leads to underestimation of system variability, reinforcing the perception that sarcoidosis is unpredictable when, in reality, it is operating within partially observed conditions. By correcting for diagnostic friction, DM™ aligns population-level modeling with real-world system behavior, strengthening both clinical interpretation and economic projections.
2. Immunopathogenesis: Granulomas as Evidence of Immune Persistence
The defining feature of sarcoidosis, the granuloma, is often described as a structured aggregation of immune cells, but functionally it represents a contained yet unresolved immune response. Granulomas form when antigen exposure activates macrophages and T cells in a coordinated manner, but the system fails to fully eliminate the underlying stimulus, leading to a state in which immune activity is sustained rather than resolved. This process begins with antigen presentation through HLA class II molecules, followed by activation of CD4+ T cells and polarization toward Th1 and Th17 immune responses, which then recruit and activate macrophages to form the cellular architecture of the granuloma (Judson, 2020). In a typical immune response, this sequence would lead to pathogen clearance and restoration of equilibrium, but in sarcoidosis, the system stabilizes around persistence.
A key feature of this persistence is impaired antigen processing and clearance, which allows immune signaling to continue even in the absence of effective resolution. Rather than representing an overactive immune system in a general sense, sarcoidosis reflects a specific failure of resolution mechanisms, where the immune system remains engaged but is unable to complete its intended function. This distinction is important because it shifts the focus from suppressing inflammation broadly to understanding why the system is unable to exit its activated state. The granuloma, in this context, becomes not just a pathological finding but a structural marker of immune stasis, indicating that the system has reached a point of equilibrium that is stable but maladaptive.
Recent research has further clarified that granulomas themselves are not uniform, but exist along a spectrum of immune configurations that correspond to different disease behaviors. Early-stage granulomas tend to be dominated by M1-like macrophages associated with inflammatory responses, while more progressive or fibrotic forms show a shift toward M2-like macrophages, which are linked to tissue remodeling and chronicity. One particularly important subtype has been identified in which Th17.1 cells interact with M2-like macrophages through the CD47/SIRPα pathway, impairing phagocytosis and antigen clearance while reinforcing persistent inflammation and resistance to glucocorticoid therapy (Zhao et al., 2025). This interaction provides a mechanistic explanation for why certain patients do not respond to standard treatments and why disease progression occurs despite intervention.
T-cell dynamics further contribute to this picture, as sarcoidosis is characterized by increased Th1 and Th17 signaling alongside dysregulated regulatory T-cell function, creating an environment in which immune activation is sustained but insufficiently controlled (Rivera & Israël-Biet, 2025). These patterns are not consistent across all patients, which reinforces the idea that sarcoidosis is composed of multiple immune states rather than a single uniform process. This variability aligns with CYNAERA’s immune clustering frameworks, such as NeuroVerse™, where symptom patterns and immune signatures are mapped into functional subgroups that can be used to guide intervention strategies (Adinig, 2026). Understanding granulomas as dynamic and state-dependent structures rather than static lesions opens the door to more precise approaches that target the mechanisms of persistence rather than the presence of inflammation alone.
3. Genetic Architecture and the Case for Phenotype-Based Stratification
Advances in genetic research have significantly improved our understanding of sarcoidosis, but perhaps more importantly, they have clarified the disease’s complexity rather than simplified it. Sarcoidosis does not arise from a single genetic mutation or pathway, but instead reflects a distributed network of susceptibility loci that influence immune behavior in different ways across individuals. Among the most consistently identified genetic associations are HLA class II genes, particularly HLA-DRB1, which play a central role in antigen presentation and T-cell activation, as well as IL23R and related pathways that regulate Th17 signaling and inflammatory responses (Liao et al., 2023; Yuan et al., 2025). These findings reinforce the importance of adaptive immunity in disease development while also highlighting that genetic risk operates within a broader system.
The variability in clinical presentation and disease trajectory suggests that these genetic factors contribute to the formation of distinct phenotypes and endophenotypes, each with its own biological and clinical characteristics. Patients may differ in terms of organ involvement, disease severity, progression risk, and response to treatment, and these differences are increasingly linked to underlying molecular and immune profiles (Rivera & Israël-Biet, 2025). For example, certain cytokine signaling patterns or gene expression signatures may correlate with acute, self-limiting disease, while others are associated with chronic inflammation or fibrosis. Imaging-based phenotyping, such as HRCT and PET-CT, further supports the existence of distinct subgroups by revealing patterns of organ involvement and inflammatory activity that are not captured by traditional classification systems.
This growing body of work points toward a clear shift from diagnosis-based thinking to mechanism-based stratification. Instead of asking whether a patient has sarcoidosis, the more relevant question becomes which subtype of sarcoidosis is present and what biological processes are driving it. Several domains are emerging as central to this stratification:
Genetic susceptibility patterns, particularly HLA variants and IL23R-associated signaling
Immune signatures, including Th1 vs Th17 dominance and regulatory T-cell function
Organ-specific phenotypes, such as pulmonary, cardiac, neurologic, or multi-system involvement
Molecular and imaging markers, including cytokine profiles and HRCT/PET-defined patterns
Despite this progress, treatment strategies have not kept pace with the complexity of the disease. Current approaches rely heavily on broad immunosuppression, most commonly corticosteroids, followed by second- or third-line agents such as methotrexate or biologics, often applied without regard to the underlying phenotype driving the disease in a given patient. This contributes to inconsistent outcomes, unnecessary exposure to side effects, and prolonged periods of trial-and-error treatment. Pharmacogenetics and pharmacogenomics offer a promising avenue for improving precision by linking genetic variation to treatment response and toxicity, but these approaches remain underdeveloped in sarcoidosis and are limited when applied in isolation.
A more effective strategy requires integrating genetic data with immune-state dynamics and environmental context to create a multi-layered model of disease behavior. Genetics can identify susceptibility and potential pathways, but it does not fully determine how the disease will unfold or how a patient will respond to intervention. That requires understanding the system as a whole, including the conditions under which it is operating. This perspective is central to CYNAERA’s Composite Diagnostic Fingerprint framework, which emphasizes the integration of genetic, biological, and environmental data to define actionable patient subgroups and guide targeted intervention. As described in the white paper, A Composite Diagnostic Fingerprint for Pediatric Long COVID. By moving beyond diagnosis-based classification toward phenotype-driven stratification, it becomes possible to align treatment strategies with the mechanisms actually driving disease in each patient, setting the stage for more durable and predictable outcomes.
4. Environmental Determinants and State-Dependent Disease Behavior
If sarcoidosis is understood as a system rather than a static condition, then the environment is not a background factor but an active driver of system behavior. A growing body of evidence supports the conclusion that sarcoidosis emerges from the interaction between genetic susceptibility and environmental exposure, particularly through inhaled antigens and microbial inputs that initiate and sustain granulomatous inflammation (Judson, 2020; Liao et al., 2023; Rivera & Israël-Biet, 2025). What has been less fully integrated into clinical thinking is the extent to which these exposures continue to shape disease behavior long after onset.
Environmental inputs influence not only whether sarcoidosis develops, but how it evolves over time. Inhaled bioaerosols, microbial fragments, metal dusts, combustion products, and organic antigens have all been associated with disease risk and progression, suggesting that sarcoidosis may represent a convergence of multiple exposure-driven pathways rather than a single uniform mechanism (Newman et al., 1997; Judson, 2020; Valeyre et al., 2014). These exposures vary across geography, occupation, and socioeconomic context, introducing structural variability that is rarely accounted for in clinical models but consistently observed in epidemiologic patterns (Rybicki et al., 2001; Arkema et al., 2016). To make this relationship more explicit, the environmental architecture of sarcoidosis can be organized into several recurring exposure domains that influence immune-state stability in different ways.
The concept of state-dependent disease behavior is not unique to sarcoidosis. In conditions such as asthma and rheumatoid arthritis, disease activity is known to fluctuate based on environmental exposure, immune activation, and temporal factors, with treatment response varying accordingly (Gibson et al., 2010; Smolen et al., 2016). Similarly, environmental immunology research has demonstrated that immune function is continuously shaped by external inputs, including microbial exposure and air quality, influencing both disease onset and progression (Belkaid & Hand, 2014). Sarcoidosis reflects a more complex expression of this same underlying principle, in which immune behavior is dynamically regulated rather than fixed.
Table 1. Environmental Factors Associated with Sarcoidosis and Their State-Dependent Effects
Exposure Domain | Representative Examples | Likely Biological Influence | State-Dependent Effect |
Microbial and antigen-rich early-life exposure | Well water, nursery attendance, childhood microbial-rich environments | Alters immune conditioning, tolerance, and Th1/Th17-Treg balance | May increase long-term susceptibility and shape later immune reactivity |
Infectious or microbial antigen exposure | Mycobacterial antigens, Cutibacterium acnes, prior tuberculosis, recurrent antigen exposure | Sustains antigen presentation and granuloma-promoting immune activation | Increases risk of persistent rather than self-limited granulomatous response |
Bioaerosols and damp indoor environments | Musty odors, mold-prone housing, high humidity, organic dusts | Increases inhaled antigen burden and inflammatory stimulation | Can reinforce immune instability, persistence, and flare-prone disease behavior |
Occupational particulate exposure | Silica, metal dust, construction materials, agricultural dusts, industrial dusts | Promotes macrophage activation, antigen persistence, and chronic immune stimulation | Associated with progression, refractory disease, and exposure-linked chronicity |
Combustion and smoke exposure | Firefighting, wildfire smoke, wood stoves, fireplaces, World Trade Center dust | Amplifies inflammatory signaling and airborne particulate burden | May worsen active disease state, reduce treatment responsiveness, and increase relapse risk |
Geographic and climate-linked exposure | Seasonal variation, northern latitude, lower sunlight exposure, regional clustering | Alters environmental burden, vitamin D-related immune modulation, and exposure timing | Contributes to population-level variation in disease risk and activity |
Housing and socioeconomic exposure conditions | Poor ventilation, unstable housing, environmental crowding, exposure-linked occupations | Increases cumulative antigen load and reduces environmental recovery capacity | Sustains high-load states that make disease persistence more likely |
The influence of environment begins early. Studies examining childhood exposure patterns have shown that microbial-rich environments, well water use, and early antigen exposure may increase susceptibility to sarcoidosis, likely through long-term effects on immune conditioning and tolerance (Sawahata et al., 2025). These findings align with broader immunology literature demonstrating that early-life microbial exposure shapes Th1/Th17 balance and regulatory T-cell development, both of which are central to sarcoidosis pathogenesis (Belkaid & Hand, 2014; Olszak et al., 2012). At the same time, adult exposures such as silica, metal dust, wildfire smoke, mold-related bioaerosols, and high-humidity environments can sustain antigen presence and amplify inflammatory signaling, contributing to persistence and progression (Iannuzzi et al., 2007; Judson, 2020).
What emerges from this body of work is a fundamentally different explanation for heterogeneity. Sarcoidosis does not vary only because patients are biologically different, but because they exist within different and continuously shifting exposure conditions. The same immune system may behave differently under low versus high environmental load, and the same patient may shift between states depending on changes in air quality, housing conditions, occupational exposure, mold burden, or infection history. In that sense, environmental exposure is not merely a risk factor for disease onset. It is a continuing modifier of disease behavior.
This leads directly into a state-dependent framework. Sarcoidosis can be understood as a state-dependent disease, in which immune behavior, symptom expression, and progression risk are determined by the current configuration of the system rather than diagnosis alone. That configuration reflects the interaction between genetic predisposition, immune activation, and environmental input at a given moment in time (Rivera & Israël-Biet, 2025; Liao et al., 2023). This framing helps explain why similar patients may have very different trajectories and why treatment response can shift over time even without major changes in diagnosis.
This perspective aligns with CYNAERA’s environmental intelligence systems, particularly VitalGuard™ and MoldX™, which model how air quality, humidity, mold burden, and climate conditions influence immune-sensitive populations. CYNAERA demonstrates that controlled environmental modulation can shift immune stability and reduce flare frequency, reinforcing the idea that external conditions are integral to disease trajectory and not secondary variables (Adinig, 2026).
5. Environmental Modulation of Treatment Response and Clinical Variability
One of the most persistent challenges in sarcoidosis care is the inconsistency of treatment response. Corticosteroids remain the first-line therapy, with immunosuppressants and biologics such as methotrexate and TNF inhibitors used in refractory cases, yet outcomes vary widely even among patients with similar clinical presentations (Baughman et al., 2016; Drent et al., 2021). This variability is often attributed to genetic differences or disease severity, but these explanations do not fully account for the observed patterns in clinical practice or trial data.
A state-dependent model offers a more complete explanation by reframing treatment response as a function of system conditions at the time of intervention. Environmental exposure plays a critical role in shaping these conditions by influencing antigen load, immune activation, and regulatory balance. Persistent antigen exposure, whether from microbial sources, occupational hazards, or environmental pollutants, can sustain Th1 and Th17 signaling, reinforce macrophage activation, and prevent the system from transitioning toward resolution (Judson, 2020; Rivera & Israël-Biet, 2025). In this context, immunosuppressive therapies may reduce symptoms without eliminating the drivers of persistence, leading to partial response or relapse after tapering.
This dynamic helps explain why two patients with similar diagnoses may respond differently to the same therapy. One may be operating in a lower antigen environment with greater immune stability, while the other remains in a high-exposure state that continuously reactivates the disease process. Without measuring or accounting for these differences, clinical variability is interpreted as unpredictability rather than a structured, state-dependent phenomenon.
The implications extend beyond individual care into research and drug development. Clinical trials that do not account for environmental variability introduce unmeasured heterogeneity, reducing signal detection and increasing the likelihood of inconclusive or failed outcomes (Patterson et al., 2021; Subramanian et al., 2022). This contributes to a cycle in which potentially effective therapies are dismissed due to inconsistent results, when in reality the issue lies in patient stratification and contextual misalignment.
Within the CYNAERA framework, this variability is addressed through integrated modeling of
biological and environmental inputs. Systems such as SymCas™ and IACC Twin™ enable prediction of flare risk and disease trajectory, while environmental overlays provide context for interpreting treatment response. In CRISPR Remission for Lyme : A Flare-Aware Personalized Gene Editing Innovation, CYNAERA demonstrates that remission is not achieved solely through intervention, but through alignment between therapy and system stability, reinforcing the need for state-aware treatment strategies (Adinig, 2026).
6. Safety and the Case for State-Dependent CRISPR Remission™
As gene-editing technologies advance, sarcoidosis presents both a promising opportunity and a complex safety challenge. The identification of immune pathways involved in granuloma persistence, including Th17 signaling, macrophage polarization, and cytokine regulation, creates potential targets for intervention (Zhao et al., 2025; Rivera & Israël-Biet, 2025). However, the same heterogeneity that complicates conventional treatment also introduces significant risk when these technologies are applied without context.
The central issue is not simply what to edit, but when and under what conditions editing occurs. CRISPR-based interventions are often conceptualized as static corrections of dysregulated pathways, applied uniformly across patients with a given diagnosis. In sarcoidosis, this assumption is incomplete. Immune signaling pathways are continuously shaped by environmental exposure, antigen load, and regulatory balance, meaning that the same intervention may produce different outcomes depending on the state of the system at the time of application (Doudna, 2020; Naldini, 2019). Editing in a destabilized system may amplify risk rather than resolve disease.
To address this, we introduce a state-dependent safety model, in which intervention timing is determined by system conditions rather than diagnosis alone.
Table 2. State-Dependent Environmental–Immune Interaction Model
Environmental Load | Immune State | Granuloma Behavior | Clinical Outcome | Intervention Sensitivity |
Low (clean air, low antigen exposure, stable housing) | Balanced Th1/Th17, functional Treg | Reduced persistence, potential resolution | Remission or mild disease | High responsiveness, low risk |
Moderate (intermittent exposure, variable air quality) | Fluctuating immune activation | Partial persistence, episodic flares | Relapsing-remitting disease | Variable response |
High (chronic mold, smoke, occupational exposure) | Sustained Th1/Th17 activation, impaired regulation | Persistent granulomas, progression | Chronic disease, fibrosis risk | Low response, high relapse |
Extreme (ongoing antigen + immune dysregulation) | Immune instability, macrophage dysfunction | Progressive granuloma remodeling | Refractory disease | Poor response, high risk |
This model demonstrates that sarcoidosis behavior is not fixed, but state-dependent, with environmental load acting as a continuous modifier of immune function and disease trajectory. It reinforces that clinical variability reflects structured system differences rather than randomness (Judson, 2020; Rivera & Israël-Biet, 2025). This framework aligns with CYNAERA’s environmental intelligence systems, including VitalGuard™ and MoldX™, which quantify real-time exposure conditions and their impact on immune-sensitive populations. As demonstrated in Microdosing Air™, controlled environmental modulation can shift patients from high-risk to stable immune states, directly influencing disease behavior (Adinig, 2026).
State-Dependent Intervention Risk in CRISPR Applications
When this same logic is applied to gene editing, the implications for safety become clear. CRISPR interventions do not operate in isolation. They are introduced into a system whose behavior is already being shaped by ongoing immune activation and environmental exposure.
If editing occurs during:
high antigen load
active inflammatory signaling
or unstable regulatory conditions
then the intervention may:
fail to achieve durable effects
trigger compensatory immune activation
or destabilize existing regulatory balance
This reframes safety as a systems alignment problem, not just a molecular precision problem.
Table 3. State-Dependent CRISPR Safety Readiness Model
System Condition | Immune Stability | Environmental Load | Editing Risk | Expected Outcome |
Stabilized | High | Low | Low | Durable remission potential |
Partially Stabilized | Moderate | Moderate | Moderate | Variable durability |
Active Inflammatory State | Low | High | High | Reduced efficacy, relapse risk |
Immune Dysregulation State | Very Low | Persistent high exposure | Very High | Instability, adverse outcomes |
This model formalizes a key principle: CRISPR success in sarcoidosis is state-dependent, not diagnosis-dependent. Intervention must be gated by system readiness, not simply by disease presence.
The translation of state-dependent CRISPR Remission™ into clinical practice will require alignment with existing regulatory frameworks for gene and cell therapies. In the United States, CRISPR-based interventions are typically evaluated under FDA pathways governing biologics and advanced therapies, with emphasis on safety, manufacturing consistency, and clinical efficacy (Naldini, 2019; Doudna, 2020). A state-dependent model introduces an additional layer of complexity, as therapeutic effectiveness and safety are contingent on patient-specific system conditions at the time of intervention.
This suggests that regulatory approval may require integration of companion diagnostics or state-readiness criteria, including immune profiling, environmental exposure assessment, or biomarker-defined stability thresholds. Rather than representing a departure from existing frameworks, this approach extends current trends toward precision medicine, where therapies are increasingly paired with diagnostic tools that guide patient selection and timing. Incorporating state-dependent readiness into regulatory design could improve both safety and efficacy outcomes by ensuring that interventions are deployed under conditions most likely to support durable remission.
7. CRISPR Remission™ Framework for Sarcoidosis: A State-Dependent Intervention Model
The application of CRISPR technologies to immune-mediated diseases has largely been framed around the identification and correction of specific genetic or signaling abnormalities. In sarcoidosis, this approach is insufficient on its own. The disease is not driven by a single mutation or static pathway disruption, but by a dynamic interaction between immune signaling, antigen persistence, and environmental exposure (Liao et al., 2023; Rivera & Israël-Biet, 2025). As a result, effective intervention requires not only identifying targets, but determining when and under what conditions those targets should be modified.
CRISPR Remission™ reframes gene editing as a state-dependent process, in which intervention is guided by immune configuration, environmental load, and phenotype-specific biology. Rather than applying editing uniformly across all patients with sarcoidosis, this framework introduces a structured approach that aligns intervention timing and target selection with system readiness. This distinction is critical, as it shifts CRISPR from a static correction model to a context-aware therapeutic architecture. Within this model, sarcoidosis is approached as a set of biologically distinct subtypes, each defined by its dominant immune pathways and environmental interactions. For example, patients with Th17-dominant inflammation and impaired macrophage clearance may require different intervention strategies than those with fibrotic, M2-skewed disease. Similarly, patients with high environmental antigen exposure may require stabilization prior to intervention to reduce the risk of persistence or rebound.
The CRISPR Remission™ framework therefore operates across three integrated layers. The first layer involves phenotype identification, where patients are stratified based on immune signaling patterns, organ involvement, and molecular markers. The second layer focuses on state assessment, evaluating immune stability and environmental load to determine readiness for intervention. The third layer involves targeted editing, in which pathways such as Th17 signaling, macrophage activation, or cytokine regulation are modulated in a controlled and context-specific manner.
This layered approach reflects CYNAERA’s broader system design philosophy, in which interventions are not deployed in isolation but are integrated into a predictive model of disease behavior. In Aligned Intelligence Method (AIM™), CYNAERA outlines how complex systems require alignment across multiple domains to achieve stable outcomes, a principle that directly applies to CRISPR deployment in immune-volatile conditions (Adinig, 2026).
Table 4. CRISPR Remission™ State-Dependent Intervention Model
Layer | Domain | Key Inputs | Function | Outcome |
1 | Phenotype Identification | Genetics, immune signatures, organ involvement | Define disease subtype | Target selection |
2 | State Assessment | Immune stability, environmental load, flare risk | Determine intervention readiness | Risk reduction |
3 | Targeted Editing | Pathway-specific modulation (Th17, macrophage, cytokines) | Apply intervention in aligned state | Durable remission potential |
4 | Post-Intervention Stabilization | Environmental control, immune monitoring | Maintain system stability | Sustained remission |
This model reinforces that CRISPR success is not determined solely by target accuracy, but by alignment between intervention and system conditions.
8. Translational and Clinical Implications: From Trial Design to Real-World Deployment
The introduction of a state-dependent CRISPR framework has immediate implications for both clinical care and research design. One of the most significant challenges in sarcoidosis has been the inability to consistently translate mechanistic insights into effective therapies. This gap is not due to a lack of biological understanding, but to the difficulty of applying interventions within a heterogeneous and dynamically changing system (Drent et al., 2021; Baughman et al., 2016).
In clinical practice, treatment decisions are often made based on organ involvement and symptom severity, rather than underlying biology or system state. This leads to broad application of therapies such as corticosteroids, which may suppress inflammation without addressing the drivers of persistence, resulting in partial response or relapse. A state-dependent approach introduces a more precise strategy, where treatment is aligned with the conditions most likely to support resolution.
In research, the implications are equally significant. Clinical trials in sarcoidosis are frequently limited by heterogeneity in patient populations, which reduces the ability to detect meaningful treatment effects (Patterson et al., 2021). Without stratification based on phenotype, immune state, and environmental exposure, trials may group together patients who are biologically distinct, masking the efficacy of targeted interventions.
A state-dependent model addresses this by introducing context-aware stratification, where patients are grouped not only by diagnosis but by system configuration. This allows for:
Improved signal detection in clinical trials
Identification of responsive subgroups
Reduction in trial failure due to heterogeneity
More efficient allocation of resources
Beyond trials, this framework supports real-world deployment of advanced therapies by enabling predictive intervention planning. Instead of reacting to disease progression, clinicians can anticipate periods of instability or readiness and align interventions accordingly. This approach is consistent with CYNAERA’s Clinical Trial Simulation and predictive modeling tools, which use multi-domain inputs to forecast treatment response and optimize study design. In The Science of IACC Remission, CYNAERA demonstrates that aligning intervention timing with system stability significantly improves outcomes across chronic conditions, reinforcing the importance of state-aware deployment (Adinig, 2026).
9. Economic Impact and System-Level Value
The economic burden of sarcoidosis is substantial and often underestimated, driven by chronic disease management, multisystem involvement, prolonged corticosteroid exposure, and inconsistent treatment response (Baughman et al., 2016; Drent et al., 2021). Unlike conditions with more predictable trajectories, sarcoidosis generates costs through variability itself, including relapse cycles, refractory disease, and long-term organ damage requiring sustained care.
Traditional prevalence estimates place the U.S. sarcoidosis population at approximately 200,000 individuals (Iannuzzi et al., 2007; Arkema et al., 2016). However, these estimates assume relatively complete diagnostic capture. CYNAERA applies the Diagnostic Multiplier™ (DM™) to account for real-world diagnostic friction, including variability in provider recognition, reliance on specialist evaluation, non-specific symptom presentation, and subgroup underrecognition.
Using a DM™-adjusted estimate of approximately 240,000–250,000 individuals, sarcoidosis represents a larger and more structurally complex population than is typically modeled. Within this expanded and more accurate population context, the economic implications of variability become more pronounced. Advanced and refractory sarcoidosis cases, which may require biologics, multi-drug regimens, or emerging therapies, represent a high-cost segment of care. As CRISPR-based and other advanced interventions enter this space, cost structures will increasingly reflect not only manufacturing and delivery, but inefficiencies associated with response variability, including non-response, partial response, relapse, and adverse events.
9.1 Modeling Variability-Driven Cost Inefficiency
Let:
P = total sarcoidosis population (DM™ adjusted: 250,000)
E = eligible moderate-to-severe/refractory population (~25%) → 62,500 patients
C_t = cost per advanced intervention (modeled CRISPR-based therapy: $300,000)
R_d = durable response rate
R_p = partial response rate
R_n = non-response rate
Total system cost:
Total Cost = E × C_t → 62,500 × $300,000 = $18.75 billion
Cost per durable responder:
Cost per Durable Responder = Total Cost / (E × R_d)
When durable response rates are limited, cost per effective outcome increases disproportionately, particularly in diseases with persistent or relapsing behavior.
9.2 Impact of State-Dependent Optimization
A state-dependent CRISPR Remission™ framework improves alignment between intervention and system conditions, increasing durable response rates without requiring new molecular targets or expanded treatment volume.
Example:
Baseline durable response: R_d = 30%
Optimized durable response: R_d = 40%
Then:
Relative Efficiency Gain = 40 / 30 = 1.33× improvement
This translates to:
33% more durable responders from the same treated population
Reduced cost per responder
Reduced need for retreatment or escalation
9.3 Reduction in Downstream Costs
Improved alignment between intervention and system state reduces downstream cost burden associated with disease persistence and treatment inefficiency.
These include:
Reduced long-term corticosteroid complications, including diabetes, osteoporosis, and infection risk (Baughman et al., 2016)
Fewer hospitalizations due to pulmonary, cardiac, or neurologic flares
Reduced dependence on biologics and combination immunosuppression
Lower progression to fibrosis and end-stage organ involvement
Even modest improvements in response predictability can shift a meaningful proportion of patients from partial or non-response into durable remission, producing compounding system-level savings.
Example: Cost Efficiency Before and After State-Dependent Optimization
To illustrate the economic impact of improved response predictability, consider a modeled cohort of sarcoidosis patients eligible for advanced intervention.
Assumptions
Total U.S. sarcoidosis population (DM™ adjusted): 250,000
Eligible moderate-to-severe population (E): 25% → 62,500 patients
Treatment cost per patient (C_t): $300,000
Baseline durable response rate (R_d): 30%
Optimized durable response rate (R_d*): 40%
Baseline Model
Total treated cost: 62,500 × $300,000 = $18.75 billion
Durable responders: 62,500 × 0.30 = 18,750 patients
Cost per durable responder: $18.75B / 18,750 = $1.0 million per responder
State-Dependent Optimized Model
Durable responders: 62,500 × 0.40 = 25,000 patients
Cost per durable responder: $18.75B / 25,000 = $750,000 per responder
Impact
+6,250 additional durable responders
~25% reduction in cost per durable responder
No increase in treatment volume or manufacturing cost
Downstream savings from reduced progression and retreatment not yet included
Interpretation
This model demonstrates that even modest improvements in response predictability produce disproportionate economic gains. The increase from 30% to 40% durable response does not simply improve clinical outcomes. It materially alters the cost structure of therapy. Importantly, this improvement does not require new drug classes, new gene targets, or expanded manufacturing pipelines. It results from improved alignment between intervention and system state.
Key Insight
In high-cost, variable-response diseases such as sarcoidosis, response predictability functions as a force multiplier. Small gains in state-dependent alignment produce large gains in both clinical and economic outcomes.
9.4 System-Level Economic Impact
Metric | Current Model | State-Dependent Model |
Durable Response Rate | Lower, variable | Increased, stratified |
Cost per Responder | High | Reduced |
Trial Efficiency | Low, heterogeneous | Improved, signal-rich |
Retreatment Burden | High | Reduced |
Long-Term Complications | High | Reduced |
Market Confidence | Variable | Increased |
CYNAERA System Positioning
Within CYNAERA, this economic shift is not theoretical. It is operationalized through integrated systems including SymCas™, VitalGuard™, MoldX™, and IACC Twin™, which collectively enable predictive modeling of disease behavior and intervention response. By aligning intervention with system conditions, CYNAERA transforms sarcoidosis from a condition managed through reactive care into one governed by state-dependent, intelligence-driven infrastructure. This approach is consistent with CYNAERA’s broader economic modeling philosophy, where system-level efficiency is achieved not through new therapies alone, but through alignment between intervention and system state, as outlined in The Science of IACC Remission (Adinig, 2026).
While the state-dependent framework provides a more accurate model of sarcoidosis behavior, its implementation requires integration of multi-domain data, including immune signaling, environmental exposure, and patient-specific variability. These data streams are not yet routinely captured in standard clinical practice, which may limit immediate scalability. However, advances in digital health, environmental monitoring, and biomarker profiling are rapidly closing this gap, suggesting that state-dependent modeling represents a near-term evolution rather than a distant paradigm.
10. Conclusion: Toward State-Dependent Remission in Sarcoidosis
Sarcoidosis has long resisted simple classification, not because it is unknowable, but because it has been approached through models that assume stability in a system that is inherently dynamic. The disease reflects the interaction of genetic susceptibility, immune dysregulation, and environmental exposure, producing a spectrum of outcomes that cannot be fully explained by any single domain alone (Liao et al., 2023; Rivera & Israël-Biet, 2025; Judson, 2020). What appears as variability is, in reality, the predictable behavior of a system operating under different conditions.
This paper reframes sarcoidosis as a state-dependent disease, in which immune behavior, disease progression, and treatment response are determined by the configuration of the system at a given moment. Within this framework, granulomas represent not merely inflammation, but evidence of immune persistence driven by unresolved antigen exposure and dysregulated immune signaling. Genetic architecture defines susceptibility and potential pathways, but it does not dictate outcome. Environmental inputs and immune-state dynamics act as continuous modifiers, shaping whether the disease resolves, persists, or progresses. The introduction of CRISPR Remission™ extends this understanding into intervention design. Rather than treating gene editing as a static correction applied uniformly across patients, this framework positions CRISPR as a state-dependent therapeutic process, requiring alignment between intervention, immune stability, and environmental conditions. This shift is essential for both efficacy and safety, as editing within an unstable system risks reinforcing dysregulation rather than resolving it (Doudna, 2020; Naldini, 2019).
By integrating phenotype stratification, immune-state assessment, and environmental modeling, it becomes possible to move beyond reactive care toward predictive, context-aware intervention. This approach addresses not only clinical variability but also the structural inefficiencies that arise from treating a dynamic disease with static models. As demonstrated through CYNAERA’s modeling systems, aligning intervention with system state improves response predictability, reduces downstream costs, and creates a pathway toward durable remission (Adinig, 2026). The implications extend beyond sarcoidosis. Many immune-mediated and post-infectious conditions exhibit similar patterns of variability, persistence, and environmental sensitivity. A state-dependent framework therefore represents not only a disease-specific advancement, but a broader shift in how complex chronic conditions are understood and treated. Sarcoidosis does not require a single breakthrough to be solved. It requires a model that reflects how it actually behaves. Once that alignment is achieved, the path to remission becomes not only clearer, but more attainable.
Frequently Asked Questions
What is meant by “state-dependent” sarcoidosis?
State-dependent sarcoidosis refers to the idea that disease behavior is determined by the current condition of the system rather than diagnosis alone. That includes immune activation, antigen load, regulatory balance, and environmental exposure at a given moment in time. Under this model, the same patient may move through different disease states over time, which means treatment effectiveness depends not only on what is used, but when and under what conditions it is applied.
How is CRISPR Remission™ different from traditional gene-editing approaches?
Traditional CRISPR approaches usually focus on correcting a specific molecular target without fully accounting for changes in system state. CRISPR Remission™ introduces a state-dependent framework in which intervention is guided by immune stability, environmental conditions, and phenotype-specific biology. This creates a more precise and safety-aware model for deployment, especially in immune-volatile diseases where timing and context materially affect outcome.
Why is environmental exposure important in sarcoidosis?
Environmental exposure matters because sarcoidosis is deeply shaped by inhaled antigens, microbial inputs, occupational exposures, and air quality conditions that can both initiate and sustain granulomatous inflammation. These exposures do not simply contribute to disease onset. They continue to affect immune-state stability, treatment response, and disease persistence across time, which is why they must be considered in both therapeutic planning and safety modeling.
Can sarcoidosis be cured with CRISPR?
At present, the evidence does not support a single curative edit for sarcoidosis. A more realistic and defensible goal is durable remission, achieved by modulating key immune pathways within a state-dependent framework. This recognizes that disease persistence arises from multiple interacting factors, including immune dysregulation, antigen persistence, and environmental load, rather than one isolated target.
How does this framework improve treatment outcomes?
This framework improves treatment outcomes by aligning intervention with system conditions. Patients are more likely to benefit when therapies are introduced during periods of greater immune stability and lower environmental burden, rather than during active instability. That improves the likelihood of durable response while reducing relapse, retreatment, and downstream complications.
What role does CYNAERA play in this model?
CYNAERA provides the infrastructure layer for implementing this approach. Systems such as SymCas™, VitalGuard™, MoldX™, and IACC Twin™ allow for flare prediction, environmental risk modeling, exposure-sensitive interpretation, and patient-specific trajectory simulation. Together, they make it possible to move from reactive disease management toward predictive, context-aware intervention planning.
Why is safety considered state-dependent in this model?
Safety is state-dependent because intervention risk changes according to the condition of the system at the time of treatment. Editing during active inflammation, high antigen load, or environmental instability may reduce effectiveness or increase the risk of adverse outcomes. A state-dependent safety model therefore treats stability as a precondition for intervention, not a hopeful byproduct of it.
Does the state-dependent framework apply only to sarcoidosis?
No. Sarcoidosis is a strong model condition, but the framework extends across a wide range of immune-mediated and infection-associated chronic illnesses. This includes Long COVID, ME/CFS, PTLD, chronic Lyme disease, MCAS, dysautonomia, POTS, fibromyalgia, lupus, rheumatoid arthritis, Sjögren’s syndrome, multiple sclerosis, CIRS, and related post-infectious syndromes. It also has relevance for pediatric immune-triggered conditions such as PANS and PANDAS, as well as chronic sequelae following infections like dengue, chikungunya, Ebola, Zika, and malaria. These conditions differ in presentation, but many share the same broad structure of immune dysregulation, environmental sensitivity, and variable disease trajectory.
Can this framework be applied to cancer or other non-immune diseases?
Yes, especially where treatment response is shaped by immune signaling, microenvironment, or systemic state. Melanoma is one obvious example, but similar logic may apply to other immunotherapy-responsive cancers, hematologic malignancies treated with cell therapies, and chronic inflammation-linked cancers. In those settings, state-dependent modeling can help improve response predictability, safety, and economic efficiency.
Why is this framework relevant across so many conditions?
It is relevant because many modern chronic diseases are not single-pathway disorders. They are multi-system conditions shaped by immune activity, environmental exposure, and system stability over time. Static models flatten that complexity. A state-dependent framework recognizes it and gives clinicians, researchers, and developers a way to intervene with more precision.
Key takeaway
Sarcoidosis and related conditions are not inherently unpredictable. They have been under-modeled. When disease is understood as state-dependent, and intervention is aligned with system conditions, variability becomes structured and remission becomes a more tractable problem.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID, ME/CFS and CRISPR Remission Libraries are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Adinig, C. (2026). The Science of IACC Remission. CYNAERA Institute.
Adinig, C. (2026). Microdosing Air™: Rebuilding Environmental Tolerance in Long COVID and Related Conditions. CYNAERA Institute.
Adinig, C. (2026). The Moral Adinig Method™: A Framework for Harm-Aware AI and Intervention Design. CYNAERA Institute.
Adinig, C. (2026). Aligned Intelligence Method (AIM™). CYNAERA Institute.
Arkema, E. V., Cozier, Y. C., & Costenbader, K. H. (2016). Epidemiology of sarcoidosis: Current findings and future directions. Therapeutic Advances in Chronic Disease, 7(4), 203–215.
Baughman, R. P., Valeyre, D., Korsten, P., et al. (2016). ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 48(3), 767–794.
Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141.
Bokhari, S. R. A., et al. (2023). Sarcoidosis: Clinical manifestations and pathophysiology. StatPearls Publishing.
Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236.
Drent, M., Crouser, E. D., & Grunewald, J. (2021). Challenges of sarcoidosis and its management. New England Journal of Medicine, 385(11), 1018–1032.
Iannuzzi, M. C., Rybicki, B. A., & Teirstein, A. S. (2007). Sarcoidosis. New England Journal of Medicine, 357(21), 2153–2165.
Judson, M. A. (2020). Environmental risk factors for sarcoidosis. Frontiers in Immunology, 11, 1340.
Liao, S.-Y., Fingerlin, T. E., & Maier, L. A. (2023). Genetic predisposition to sarcoidosis. Journal of Autoimmunity, 135, 103122.
Naldini, L. (2019). Gene therapy returns to centre stage. Nature, 526(7573), 351–360.
Olszak, T., An, D., Zeissig, S., et al. (2012). Microbial exposure during early life has persistent effects on natural killer T cell function. Science, 336(6080), 489–493.
Patterson, B. K., et al. (2021). Immune-based stratification challenges in chronic inflammatory disease trials. Frontiers in Medicine, 8, 678.
Rivera, N. V., & Israël-Biet, D. (2025). Sarcoidosis in the genomic era: From genetic drivers to tailored therapies. Current Opinion in Pulmonary Medicine, 31(2), 100–110.
Rybicki, B. A., Major, M., Popovich, J., et al. (2001). Racial differences in sarcoidosis incidence. American Journal of Epidemiology, 153(10), 983–991.
Sawahata, M., Arai, N., Kamei, R., et al. (2025). Childhood hygiene environment and risk of sarcoidosis. Respiratory Investigation.
Subramanian, A., et al. (2022). Heterogeneity and signal detection challenges in clinical trials. Nature Medicine, 28(4), 789–797.
Valeyre, D., Prasse, A., Nunes, H., et al. (2014). Sarcoidosis. Lancet, 383(9923), 1155–1167.
Yuan, X., et al. (2025). Genome-wide association study identifies immune-related loci in sarcoidosis. Nature Genetics.
Zhao, Y., et al. (2025). Macrophage–Th17.1 interactions drive sarcoidosis progression. Journal of Clinical Investigation.
Comments